At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 150 enrolled
Drug / intervention
Dehydroepiandrosterone +1 moredrug
Likely dose
Dehydroepiandrosterone 3.0 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of DHEA on Skin Aging - Placebo-Controlled and Randomized Phase III Study in Postmenopausal Women.
In Brief
A Phase 3 clinical trial evaluating Dehydroepiandrosterone and Placebos for Skin Aging and Quality of Life. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The purpose of the study is to determine the response of skin parameters related to skin aging to the local action of DHEA in postmenopausal women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Aging, Quality of Life
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2004
First PostedNov 2005
Primary CompletionNov 2005
Study CompletionNov 2008
TodayJul 2026
First PostedNov 4, 2005
Enrollment StartNov 1, 2004
Primary CompletionNov 24, 2005
Study CompletionNov 13, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 20.7 years ago
Interventions
Dehydroepiandrosteronedrug
3.0 ml of 0.3% DHEA cream applied on the skin twice daily.
Placebosdrug
3.0 ml of placebo cream applied on the skin twice daily.